does tirzepatide cause osteoporosis Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites Tirzepatide Mechanism of Weight Loss

Hypoglycemia is a risk when tirzepatide is used in combination with insulin or insulin secretagogues (such as sulfonylureas)

It is not recommended for research protocols requiring precise dosing and reproducibility

Diffuse idiopathic skeletal hyperostosis (DISH) is a spine disorder that results in bone growth along the ligaments of the spine

Nearly half of all heart attack patients experience persistent narrowing of tiny blood vessels in the heart muscle even after the main blocked artery has been reopened during emergency treatment

On July 23rd, a federal advisory committee votes on whether to recommend that compounding pharmacies be allowed to make seven peptides, BPC-157, TB-500, and MOTS-c among them, that the FDA has never approved and that carry almost no human trial data

Food and Drug Administration has announced three seizures of Ozempic in the legitimate drug supply